FDA Actions vs Clinical Trials

Side-by-side coverage analysis for FDA Actions and Clinical Trials.

FDA Actions

Approvals, rejections, priority reviews

Stories
0
Avg Impact
0/10
Dominant Tone
Very Bullish

Sentiment breakdown

View all FDA Actions stories →

Clinical Trials

Phase I-III results, trial design

Stories
20
Avg Impact
6.8/10
Dominant Tone
Bullish
Latest
Mar 25, 2026

Sentiment breakdown

View all Clinical Trials stories →

Recent Headlines

FDA Actions

No recent stories found.

Clinical Trials

  1. Bullish ●●○
    Hope Medicine Doses First Patient in Phase III Trial for Endometriosis Therapy
  2. Bullish ●●○
    Pfizer's Lyme Vaccine Shows Over 70% Efficacy in Pivotal Phase 3 Trial
  3. Bullish ●●○
    Hope Medicine Doses First Patient in Phase III Endometriosis Trial for HMI-115
  4. Very Bullish ●●●
    Innovent's IBI302 Hits Phase 3 Goal, Pioneering Extended nAMD Care in China
  5. Bullish ●●○
    Monash University and ClinChoice Partner to Accelerate Clinical Development
  6. Very Bullish ●●●
    First Lab-Grown Oesophagus Breakthrough Offers Hope for Rare Pediatric Conditions
  7. Bullish ●●○
    iBio Targets Q3 for Lead Bispecific Candidate in PH-HFpEF Treatment
  8. Neutral ●●○
    RBC Capital Backs Eli Lilly’s Retatrutide as Next-Gen Obesity Powerhouse
  9. Neutral ●●○
    Curis Completes Strategic Pivot to Oncology Pipeline Following Erivedge Sale
  10. Bullish ●●○
    Acumen Pharmaceuticals Targets 2026 Milestone for Alzheimer’s Antibody